Naloxone extended release - SLA Pharma

Drug Profile

Naloxone extended release - SLA Pharma

Alternative Names: Nalcol; Naloxone hydrochloride; Naloxone SR

Latest Information Update: 12 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SLA Pharma
  • Class Antidotes; Benzofurans; Drug withdrawal therapies; Isoquinolines; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation

Most Recent Events

  • 14 May 2012 Naloxone extended release is available for partnering as of 14 May 2012.
  • 14 May 2012 Efficacy and adverse events data from a phase II trial in Constipation (opioid-induced) released by SLA Pharma
  • 21 Feb 2012 SLA Pharma completes a phase II trial in Constipation in United Kingdom (EudraCT2009-011853-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top